Literature DB >> 23312662

Neurorehabilitation in Parkinson disease.

Neil Archibald1, Nick Miller, Lynn Rochester.   

Abstract

Parkinson disease (PD) is the second commonest neurodegenerative disorder in the UK with an increasing prevalence in our aging population. The clinical features of PD are varied with a variety of "motor" and "nonmotor" symptoms and the condition is best thought of as a multisystem neurodegenerative disorder rather than as a "pure" movement disorder. Although the mainstay of treatment is pharmacological, nonpharmacological interventions are vital as part of a multidisciplinary approach to the disorder. Neurorehabilitative interventions have been used for some time in the treatment of PD but, until recently, there has been little evidence to support the clinical impression that physiotherapy, occupational therapy, and speech and language therapy have a positive impact on both motor and nonmotor symptoms. This chapter will review the current evidence base for neurorehabilitation in PD and discuss the challenges of service provision within healthcare systems.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23312662     DOI: 10.1016/B978-0-444-52901-5.00037-X

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  11 in total

1.  Where Do Parkinson's Disease Patients Look While Walking?

Authors:  Nora Vanegas-Arroyave; Denise F Chen; Peter M Lauro; Gina Norato; Codrin Lungu; Mark Hallett
Journal:  Mov Disord       Date:  2022-01-08       Impact factor: 9.698

2.  The neuromuscular responses in patients with Parkinson's disease under different conditions during whole-body vibration training.

Authors:  Chia-Ming Chang; Chon-Haw Tsai; Ming-Kuei Lu; Hsin-Chun Tseng; Grace Lu; Bey-Ling Liu; Hsiu-Chen Lin
Journal:  BMC Complement Med Ther       Date:  2022-01-03

3.  Furthering our understanding of the needs of adolescent children of parents with Parkinson's disease.

Authors:  David Morley; Crispin Jenkinson
Journal:  Adolesc Health Med Ther       Date:  2013-07-29

4.  Changes in vowel articulation with subthalamic nucleus deep brain stimulation in dysarthric speakers with Parkinson's disease.

Authors:  Vincent Martel Sauvageau; Joël Macoir; Mélanie Langlois; Michel Prud'Homme; Léo Cantin; Johanna-Pascale Roy
Journal:  Parkinsons Dis       Date:  2014-10-21

Review 5.  Effects of Tai Chi Exercise on Reducing Falls and Improving Balance Performance in Parkinson's Disease: A Meta-Analysis.

Authors:  Hsin-Hsuan Liu; Nai-Chen Yeh; Yi-Fan Wu; Yea-Ru Yang; Ray-Yau Wang; Fang-Yu Cheng
Journal:  Parkinsons Dis       Date:  2019-02-21

6.  Combining a Cognitive Concurrent Task with a Motor or Motor-Cognitive Task: Which Is Better to Differentiate Levels of Affectation in Parkinson's Disease?

Authors:  Arturo X Pereiro; Bea Resúa; David Facal; José María Cancela-Carral
Journal:  Parkinsons Dis       Date:  2020-04-04

Review 7.  Molecular Mechanisms of Astaxanthin as a Potential Neurotherapeutic Agent.

Authors:  Eshak I Bahbah; Sherief Ghozy; Mohamed S Attia; Ahmed Negida; Talha Bin Emran; Saikat Mitra; Ghadeer M Albadrani; Mohamed M Abdel-Daim; Md Sahab Uddin; Jesus Simal-Gandara
Journal:  Mar Drugs       Date:  2021-04-03       Impact factor: 5.118

8.  Articulatory Changes in Vowel Production following STN DBS and Levodopa Intake in Parkinson's Disease.

Authors:  Vincent Martel Sauvageau; Johanna-Pascale Roy; Léo Cantin; Michel Prud'Homme; Mélanie Langlois; Joël Macoir
Journal:  Parkinsons Dis       Date:  2015-10-07

Review 9.  Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation.

Authors:  Francesca Magrinelli; Alessandro Picelli; Pierluigi Tocco; Angela Federico; Laura Roncari; Nicola Smania; Giampietro Zanette; Stefano Tamburin
Journal:  Parkinsons Dis       Date:  2016-06-06

Review 10.  On the Neuroprotective Role of Astaxanthin: New Perspectives?

Authors:  Christian Galasso; Ida Orefice; Paola Pellone; Paola Cirino; Roberta Miele; Adrianna Ianora; Christophe Brunet; Clementina Sansone
Journal:  Mar Drugs       Date:  2018-07-24       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.